ArticleActas espanolas de psiquiatria2025
Effects of Electroencephalographic Biofeedback Therapy on Depression Level, Sleep Quality and Cognitive Function in Patients With Non-Demented Vascular Cognitive Impairment.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Brain-Computer Interface Technology in Vascular Cognitive Impairment: A Systematic Review.Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the effects of electroencephalographic biofeedback (EEG-BF) treatment on cognitive function, sleep quality, anxiety and depression levels and quality of life in patients with vascular cognitive impairment-no dementia (VCI-ND).
methodsThis study was a retrospective study that included a total of 128 patients diagnosed with VCI-ND at the Affiliated Hospital of North Sichuan Medical College from July 2022 to July 2024. The patients were divided into an EEG-BF group and a control group in accordance with whether they received EEG-BF treatment or not. Both groups received standard vascular risk factor management. The EEG-BF group separately received EEG-BF intervention two times a week for 12 weeks. Propensity score matching (PSM) was used to perform 1:1 nearest-neighbour matching between the two groups with respect to baseline characteristics. The matching variables included age; education; place of residence; family income; type of health insurance; number of underlying diseases; and pre-intervention scores on the Montreal Cognitive Assessment (MoCA), Pittsburgh Sleep Quality Index (PSQI), Self-rating Anxiety Scale (SAS), and Self-rating Depression Scale (SDS). The main outcome measures were the PSQI, MoCA, SAS, 36-item Short-Form Questionnaire (SF-36) and SDS before and after treatment.
resultsAfter PSM, the baseline covariates between the two groups were well balanced, with no significant differences. The Love plot showed a significant decrease in standardised differences in covariates after matching. After 12 weeks of intervention, the EEG-BF group was significantly better than the control group in terms of MoCA scores (p = 0.013), SAS scores (p = 0.002), SDS scores (p = 0.004) and some of the SF-36 dimensions, and the within-group before and after comparisons was statistically different (p < 0.05). The sleep quality of the EEG-BF group improved after treatment, whereas that of the control group exhibited no notable variation before and after the intervention (p > 0.05).
conclusionEEG-BF may help improve cognitive function, sleep quality, emotional state and life quality in patients with VCI-ND, offering a promising individualised non-pharmacological intervention for this population. Future multicentre, prospective studies are needed to further validate its prolonged therapeutic effect and neuromodulatory mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.